Biomedical subjects

M A Campanero

Publications and source records attributed to M A Campanero.

At least 19 recordsLinked to original sources

PubMed2007

Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.

Drug delivery systems containing gentamicin were studied as a treatment against experimental brucellosis in mice. Micro- and nanoparticles prepared by using poly(D,L-lactide-coglycolide) (PLGA) 502H and microparticles made of PLGA 75:25H were successfully delivered to the liver and the spleen, the target organs for Brucella melitensis. Both polymers have the same molecular weight but have different lactic acid/glycolic acid ratios. Microparticles of PLGA 502H and 75:25H released their contents in a sustained manner, in contrast to PLGA 502H nanoparticles, which were degraded almost completely during the first week postadministration. The values of the pharmacokinetic parameters after administration of a single intravenous dose of 1.5 mg/kg of body weight of loaded gentamicin revealed higher areas under the curve (AUCs) for the liver and the spleen and increased mean retention times (MRTs) compared to those for the free drug, indicating the successful uptake by phagocytic cells in both organs and the controlled release of the antibiotic. Both gentamicin-loaded PLGA 502H and 75:25H microparticles presented similar pharmacokinetic parameter values for the liver, but those made of PLGA 75:25 H were more effective in targeting the antibiotic to the spleen (higher AUCs and MRTs). The administration of three doses of 1.5 mg/kg significantly reduced the load associated with the splenic B. melitensis infection. Thus, the formulation made with the 75:25H polymer was more effective than that made with 502H microspheres (1.45-log and 0.45-log reductions, respectively, at 3 weeks posttreatment). Therefore, both, pharmacokinetic and pharmacodynamic parameters showed the suitability of 75:25H microspheres to reduce the infection of experimentally infected mice with B. melitensis.

Animals↗

PubMed2006

Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles.

Nanoparticles based on the poly(methyl vinyl ether-co-maleic anhydride) were pegylated with different types of PEGs, namely, two hydroxyl-functionalized PEGs (PEG and mPEG) and two amino-PEGs (DAE-PEG and DAP-PEG). The resulted nanoparticles demonstrated reduction of the negative surface charge compared to the non-modified particles. Further, in vivo experiments showed that all types of pegylated particles possessed higher affinity to adhere to intestinal rather than to the stomach mucosa. Higher bioadhesive potential was observed in the case of PEG-NP and DAE-PEG-NP which was attributed to the flexibility and specific properties of the surface "brush" layer of these particles. The lower bioadhesive potential of mPEG-NP was due to the low presence of coating "brush" layer, whereas for DAP-PEG-NP to the fact that the double end coupled chains ("loop"-conformation) were not available for intensive interactions with the mucosa. The observations made by optic microscopy illustrated an intracellular transport of PEG-NP in vivo with preferable location in the apical area of enterocytes.

Adhesiveness↗

PubMed2005

Simultaneous quantification of different cyclodextrins and Gantrez by HPLC with evaporative light scattering detection.

A rapid and simple HPLC method with evaporative scattering detection (ELSD) has been developed for the separation and quantitation of beta-cyclodextrin (beta-CD), 2-hydroxypropyl-beta-cyclodextrin (2-HP-beta-CD) and poly(methyl vinyl ether-co-maleic anhydride) (Gantrez). Separation was carried out on a Zorbax Eclipse XDB-Phenyl narrow bore column, with water-acetonitrile in gradient elution as mobile phase at a flow-rate of 0.25 ml/min. Polyethylenglycol 6000 was used as internal standard. The limit of quantification was of about 0.2 mg/ml for cyclodextrins and 0.05 mg/ml for Gantrez. The precision did not exceed 7%. This method was successfully applied to the rapid analysis of CD-Gantrez nanoparticle conjugates without interference from other components of the formulation.

2-Hydroxypropyl-beta-cyclodextrin↗

PubMed2004

Clinical relevance of sirolimus drug interactions in transplant patients.

Sirolimus, a new immunosuppressant drug; is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate of the P-glycoprotein drug efflux pump. The CYP3A4/P-glycoprotein system is mainly localized in the liver and intestine. It is responsible for the severe first pass metabolism of sirolimus with a low bioavailability. Drugs like voriconazole, itraconazole, fluconazole, and erytrhomycin may decrease the metabolic activity of this enzymatic system. This report documents in five patients that coadministration of these antimicrobials with sirolimus increases the blood concentrations of the immunosuppressant. The dose-normalized trough blood concentration showed a mean increase of sevenfold with the coadministration of these drugs. It is essential to monitor the blood sirolimus concentrations and to adjust the sirolimus doses before and after coadministration of these drugs.

Aged↗

PubMed2004

Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome.

The in-vitro susceptibility of an organism and the pharmacokinetics of an antimicrobial agent are two basic factors on which the choice of standardised treatment regimens is based. However, the inter-individual variability of these factors, which modifies the exposure of bacteria to an antibiotic in terms of time and quantity, is not usually taken into account. In 87 patients treated with beta-lactams (ceftriaxone, cefepime or piperacillin), the probability of failure was greater when the infectious process was located in tissues with barriers to the distribution of beta-lactams. Mean MICs of piperacillin and cefepime, but not ceftriaxone, were below the breakpoints in cases of both recovery and failure, but organisms isolated from patients with a poor outcome had higher MICs. Therefore, the use of breakpoints to determine the susceptibility of microorganisms was not satisfactory in predicting the outcome for a large number of patients. If MICs are determined and plasma concentrations are monitored, dosages can be adjusted according to these parameters, thereby allowing antibiotic treatment to be individualised.

Adult↗

PubMed2003

Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.

OBJECTIVE: To study the toxicity and activity of two new amphotericin B formulations: poly(epsilon-caprolactone) nanospheres coated with poloxamer 188 (AmB-NP) and mixed micelles with the same surfactant (AmB-MM). MATERIALS AND METHODS: The toxicity of these formulations was evaluated in erythrocytes, J774.2 macrophages and LLCPK1 renal cells, as well as in mice. Activity was determined in clinical isolates and in neutropenic mice. Mice were made neutropenic with 5-fluorouracil, infected with Candida albicans and treated with the antifungal formulations for three consecutive days. AmB association in cells and accumulation in kidneys and liver of animals was quantified by HPLC. RESULTS: Both formulations decreased between 8- and 10-fold the MIC of the polyene against clinical isolates of C. albicans. However, their activity was lower than or equal to that of AmB-deoxycholate when it was assessed against C. albicans-infected macrophages. When given as a single intravenous dose in mice, AmB-MM and AmB-NP had an LD50 of 9.8 and 18.6 mg/kg, respectively, compared with 4 mg/kg for AmB-deoxycholate. Comparison of residual infection burdens in the liver and kidneys showed that AmB-deoxycholate (0.5 mg/kg) was more effective and faster in eradicating yeast cells than polymeric formulations. This fact can be related to a lower AmB accumulation inside macrophages and in liver and kidneys (about 1.5 mg drug/g tissue) of mice, compared with those detected for AmB-deoxycholate (4 mg drug/g). Overall, the efficacy of these formulations at 2 mg/kg was equal to that of AmB-deoxycholate at 0.5 mg/kg. CONCLUSIONS: AmB-MM and AmB-NP decreased the in vivo antifungal activity of AmB, and higher concentrations were therefore necessary to obtain a similar therapeutic effect. However, these higher concentrations were achievable owing to the reduced toxicity of these formulations.

Amphotericin B↗

PubMed2003

Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties.

The aim of this work was to investigate the influence of the cross-linkage of poly(methylvinylether-co-maleic anhydride) (PVM/MA) nanoparticles with increasing amounts of 1,3-diaminopropane (DP) and, eventually, bovine serum albumin (BSA) on their gastrointestinal transit and bioadhesive properties. The fluorescently-labelled formulations were orally administered to rats and, at different times, the amount of nanoparticles in both the lumen content and adhered to the gut mucosa were quantified. The gut transit was evaluated by calculating the gastric (k(ge)) and intestinal (k(ie)) emptying rates. The adhered fraction of nanoparticles in the whole gut was plotted versus time and, from these curves, the intensity, capacity and extent of the adhesive interactions were estimated. The bioadhesive potential of PVM/MA was much higher when formulated as nanoparticles (NP) than in the solubilised form in water. However, k(ge) and k(ie) increased by increasing the extent of cross-linkage of nanoparticles with DP, while the capacity to develop adhesive interactions and the intensity of the adhesive phenomenon were significantly higher for non-hardened than for DP-cross-linked carriers. In contrast, the BSA-coating of cross-linked nanoparticles significantly decreased k(ge) and k(gi), whereas the intensity of the bioadhesive phenomenon was significantly higher than for NP. In summary, the adhesivity of the nanoparticles appears to modulate their gastrointestinal transit profile.

Adhesiveness↗

PubMed2002

Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles.

This work describes the bioadhesive properties of poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA) nanoparticles fluorescently-labelled with rhodamine B isothiocyanate, and coated with either Sambucus nigra lectin (SNA-NP) or bovine serum albumin (BSA-NP). The different formulations (10 mg) were administered to animals by the oral route and the fraction of adhered particles to the mucosa was estimated by measuring the fluorescent marker after the digestion of the tissue. Plotting the amount of adhered particles in the whole gut versus time enabled us to determine the affinity of the formulation for the biological support (expressed as Q(max)), the intensity and relative duration of the bioadhesive phenomenon (AUC(adh) and MRT(adh), respectively), and the elimination rate of the adhered particles (k(adh)). SNA-NP displayed a similar adhesive affinity and adhesive intensity for the gut mucosa than the control particles; although, its maximum of interaction with the mucosa was observed 1 h post-administration, whereas control and BSA-NP took place only 30 min post-administration. On the other hand, the coating of nanoparticles with SNA significantly reduced the k(adh) (P<0.01) and, thus, MRT(adh) was 35 min longer for the lectin-conjugate than for the control. BSA-NP displayed a highest initial affinity for the gut mucosa and AUC(adh) was calculated to be 1.5 fold higher than for the control or SNA-NP. However, BSA-NP were eliminated more rapidly from the mucosa than SNA-NP and, thus, the MRT(adh) was only 27 min longer than control. In summary, the parameters describing the bioadhesive profile of a given formulation may be useful to quantify the potential of colloidal particulates to interact with a mucosa and to evaluate the influence of different ligands on the bioadhesive properties of the resulting drug carriers.

Adhesives↗

PubMed2002

Determination of cidofovir in both skin layers and percutaneous penetration samples by HPLC.

The aim of this study was to develop a direct, simple and rapid high performance liquid chromatographic method for the determination of cidofovir in both skin layers and percutaneous penetration experiments. Samples were chromatographed on a reversed phase encapped column 250 x 4 mm C(8) LiChrospher Select B. The phase mobile consisted on 3% of acetonitrile and 97% of 1.5 mM of tetrabutylammonium dihydrogen phosphate (TADP) and 3.5 mM of disodium hydrogenphosphate adjusted to pH 6. Detection was at 274 nm and the run time was 14 min. The limit of detection was 0.06 microg/ml. The detector response was found to be linear in the concentration range 0.1-10 microg/ml. This assay is a selective, sensitive and reproducible method for the quantification of cidofovir in skin layers and in the receptor compartment of Franz-type diffusion cells after percutaneous studies.

Antiviral Agents↗

PubMed2002

RP-LC determination of 5-fluorouridine in nanoparticulate formulations.

5-fluorouridine (5-FUrd) is an anticancerous drug with a number of side effects due to its high toxicity. One possibility to overcome these drawbacks may consist on the use of polymeric nanoparticles to increase the therapeutic index of this drug. The objective of this study was to develop an analytical high performance liquid chromatography (HPLC) method for the determination of (i) the 5-FUrd content in poly (methyl vinyl ether-co-maleic anhydride) nanoparticles, (ii) its release from these carriers and, its eventual degradation during preparation, storage or release in 5-fluorouracil (5-FU). The chromatography was performed on a reversed-phase encapped column (LiChrospher Select B C8) with a mobile phase of 0.05 M ammonium acetate (pH 6.5). Ganciclovir (GCV) was used as internal standard and the detection wavelength was 268 nm. The limits of quantification of 5-FUrd and 5-FU were 12 and 5 ng/ml, respectively. Similarly, precision did not exceed 7%. Under our experimental conditions, the maximal drug loading capacity of 5-FUrd was around 105 microg/mg nanoparticle and the drug was released in a biphasic way from these particles. In addition, no degradation of 5-FUrd to 5-FU during either the preparative process or the release studies was observed. In summary, this HPLC method is selective, sensitive, specific and reproducible for the quantification of 5-FUrd in polymeric nanoparticles and release mediums.

Antineoplastic Agents↗

PubMed2002

Development of a chromatographic method for the determination of saquinavir in plasma samples of HIV patients.

A simple, sensitive and reproducible high-performance liquid chromatographic method for detecting and quantifying saquinavir in human plasma is described. Verapamil was used as internal standard. The method employes a single liquid-liquid extraction step with tert-butil methyl ether followed by chromatography on a Lichrospher 60 Select B C8 reversed-phase column. Ultraviolet detection was used to identify the compounds of interest. The quantitation limit of saquinavir was 1 ng/mL and only 0.5 mL of plasma sample was required for the determination. The average saquinavir recoveries over a concentration range of 2.5-500 ng/mL ranged from 86 to 95%. Precision and accuracy did not exceed 5%.

Calibration↗

PubMed2001

Improved selectivity in detection of polar basic drugs by liquid chromatography-electrospray ionization mass spectrometry. Illustration using an assay method for the determination of famotidine in human plasma.

It is well to assume that bioanalytical chromatographic methods for the determination of polar basic drugs are developed and optimised according to a standardised procedure which involves two alternatives: (a) modifications in the sample preparation procedures, and (b) changes in the stationary phase of the chromatographic system. In this paper, a simple and rapid chromatographic procedure using a specific analytical detection method (ESI tandem mass spectrophotometric detection) in combination with a fast and efficient sample work-up procedure, protein precipitation, is presented. A demonstration of the entire chromatographic procedure is given for an HPLC method for the determination of famotidine in human plasma, a basic polar drug with poor solubility in organic solvents. In order to optimize the mass detection of famotidine, several parameters such as ionization mode, fragmentor voltage, m/z ratios of ions monitored, type of organic modifier and eluent additive, were investigated. Each analysis required 5 min. The calibration curve of famotidine in the range 1-200 ng/ml was linear with a correlation coefficient of 0.9992 (n = 6), and a detection limit a signal-to-noise ratio of 3 was approximately 0.2 ng/ml. The within- and between-day variations in the famotidine analysis were 5.2 (n = 6) and 6.7% (n = 18), respectively. The applicability of this method was also demonstrated for the analysis of plasma samples in a Phase-I human pharmacokinetic study.

Biological Availability↗

PubMed2001

A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC.

A sensitive high-performance liquid chromatographic assay for the quantitative determination of gemfibrozil is described in this work. Ibuprofen was used as internal standard. The assay involved a single cyclohexane extraction and LC analysis with fluorescence detection. Chromatography was performed at 40 degrees C on a Hypersil ODS column. The mobile phase was a mixture of a solution of phosphoric acid 0.4% and acetonitrile (45:55). The method was validated. The detection limit of this method was 0.025 microg ml(-1); only 0.5 ml of the plasma sample was required for the determination. The calibration graph was linear from 0.05 to 0.5 microg ml(-1) and required a cubic equation from 0.5 to 30 microg ml(-1). Intra and inter-day precision (C.V.) did no exceed 15%. Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.

Area Under Curve↗

PubMed2001

Sensitive LC determination of piroxicam after in vitro transdermal permeation studies.

A direct, very sensitive, simple and rapid high-performance liquid chromatographic (HPLC) method for the determination of piroxicam, with tenoxicam as internal standard, has been developed and validated. Samples were chromatographed on a 5 microm Scharlau C(18) column. The mobile phase was a mixture of acetonitrile-acetic acid 4% (pH 2.8) (45:55, v/v). Detection was at 354 nm and the run time was 7 min. The limit of detection was 0.025 microg/ml. The detector response was found to be linear in the concentration range 0.05-9 microg/ml. This HPLC assay has been applied to measure the 'in vitro' percutaneous permeation of piroxicam through abdominal hairless rat skin, using Franz-type diffusion cells, in order to obtain the concentration-time profiles of piroxicam.

Administration, Cutaneous↗

PubMed2001

Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics.

PURPOSE: The aim of this work was to evaluate the bioadhesive properties of non-hardened gliadin nanoparticles (NPs) and cross-linked gliadin nanoparticles (CL-NP) in the carbazole pharmacokinetic parameters obtained after the oral administration of these carriers. METHODS: A deconvolution model was used to estimate the carbazole absorption when loaded in the different gliadin nanoparticles. In addition, the elimination rates of both adhered and non-adhered nanoparticulate fractions within the stomach were estimated. RESULTS: Nanoparticles dramatically increased the carbazole oral bioavailability up to 49% and provided sustained release properties related to a decrease of the carbazole plasma elimination rate. The carbazole release rates from nanoparticles (NP and CL-NP), calculated by deconvolution, were found to be of the same order as the elimination rates of the adhered fractions of nanoparticles in the stomach mucosa. In addition, good correlation was found between the carbazole plasmatic levels, during the period of time in which the absorption process prevails, and the amount of adhered carriers to the stomach mucosa. CONCLUSION: Gliadin nanoparticles significantly increased the carbazole bioavailability, providing sustained plasma concentrations of this lipophilic molecule. These pharmacokinetic modifications were directly related to the bioadhesive capacity of these carriers with the stomach mucosa.

Administration, Oral↗

PubMed2000

Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis.

ISIS 2922 is an antisense oligonucleotide with antiviral activity against cytomegalovirus. However, its rapid degradation in biological fluids and its low capacity for diffusion across cell membranes limit its therapeutical use. One possibility to overcome these drawbacks consists of using nanoparticles as drug carriers. The aim of this study was to develop an analytical method for determining the amount of ISIS 2922 loaded into albumin nanoparticles. For this purpose, capillary zone electrophoresis (CZE) was performed on a fused-silica capillary filled with borate buffer (12.5 mM, pH 9.5). Paracetamol was used as an internal standard and a diode-array detection system was set at 270 nm. Under these conditions, the limit of quantitation of ISIS 2922 was 1.27 microg and the precision and accuracy of the method did not exceed 7%. Moreover, the use of paracetamol as internal standard and the quantification by means of a 'corrected area' procedure enabled us to reduce the peak variability and accurately determine the amount of oligonucleotide loaded in the albumin nanoparticles. In summary, this assay is a selective and sensitive CZE method for the accurate quantitation of ISIS 2922 oligonucleotide in albumin nanoparticles.

Antiviral Agents↗

PubMed2000

Determination by high-performance liquid chromatography of ketoprofen in vitro in rat skin permeation samples.

A direct, simple and rapid high-performance liquid chromatographic method has been developed for the determination of ketoprofen with ibuprofen as internal standard. Samples were chromatographed on a 5 microm Kromasil 100 C18 column. The mobile phase was a mixture of acetonitrile-0.01 M KH2PO4 adjusted to pH 1.5 with orthophosphoric acid 85% (60:40, v/v). Detection was at 260 nm and the run time was 10 min. The detector response was found to be linear in the concentration range 0.02 to 40 microg/ml. This HPLC assay has been applied to measure the "in vitro" percutaneous penetration of ketoprofen through rat skin.

Animals↗

PubMed2000

Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography.

Ganciclovir is a nucleoside analogue widely used in the treatment of cytomegalovirus infections, which affects mainly immunocompromised patients. Recently, new pharmaceutical dosage forms based on the use of albumin nanoparticles have been developed for improving the efficacy of this drug. The aim of this study was to develop an analytical HPLC method for the determination of ganciclovir in both pharmaceuticals (i.e. albumin nanoparticles) and biological medium samples. The chromatography was performed on a reversed-phase encapped column (LiChrospher Select B C8) with a mobile phase consisting of acetonitrile in 0.05 M ammonium acetate (pH 6.5; 2: 98, v/v). Acyclovir was used as internal standard and the detection wavelength was 254 nm. The limit of quantitation of ganciclovir was 50 ng/ml and the average recoveries over a concentration range of 0.05-10 microg/ml ranged from 98 to 102%. Precision did not exceed 5%. In summary, this assay is a selective, sensitive and reproducible method for the determination of the ganciclovir in albumin nanoparticles. It can be successfully applied to the estimation of the ganciclovir uptake by cultured human corneal fibroblasts.

Antiviral Agents↗